Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution dlvr.it/T9Q1T5

💫🌟Results and Main Messages from the ESMO Recommendations on Clinical Reporting of Genomics Test Results for Solid Cancers🌟💫 OncoAlert Joaquin Mateo 📋🧬Standardized Genomics Reports: Essential for informed clinical decisions and precision oncology. 👨‍⚕️👩‍⚕️🌍Consensus-Based

🔬 | Invertir en investigación es invertir en salud. Y avances como los de Vall d’Hebron Institute of Oncology (VHIO) permiten analizar la evolución del cáncer de próstata metastásico, guiar el tratamiento y así combatir los efectos de una enfermedad que padecen más de 30 mil personas en nuestro país.

A joint effort with Joaquin Mateo, highlighting the clinical relevance, emerging molecular distinctive features and therapeutic progress in the most aggresive clinical manifestation of prostate cancer. Asociación Española Contra el Cáncer CIBERONC ASEICA sciencedirect.com/science/articl…

Not all prostate cancers are the same. A very small fraction of patients present a distinct clinical manifestation that accounts for nearly half of the mortality of this tumor type. We went hands on to study the disease emerging in these patients. biorxiv.org/content/10.110…

📢 #mHNPC, a distinct biological entity? Read our last #review!!! Thanks to Joaquin Mateo and ArkaitzCarracedoLAB sciencedirect.com/science/articl…

Tune in as we explore the cutting-edge research of Joaquin Mateo (Joaquin Mateo) from Vall d’Hebron Institute of Oncology (VHIO). In this #CORDIScovery podcast episode, Joaquin shares insights into his work on developing novel forms of precision medicine, europa.eu/!gYfGv7 Marie Skłodowska-Curie Actions

The use of PARP inhibitors in #mCRPC with BRCA1/2 alterations. Joaquin Mateo Vall d’Hebron Institute of Oncology (VHIO) and Alicia Morgans, MD, MPH Dana-Farber discuss the poor prognosis associated with these mutations but highlight the effectiveness of PARP inhibitors like olaparib and rucaparib > bit.ly/3VVDJFt

🚨 Today is your last chance to book your place at #MAP2024 with the early registration discount to join the likes of Mariam Jamal-Hanjani, Joaquin Mateo & lisaderosa – get your ticket now: bit.ly/3K5MyXG ESMO - Eur. Oncology | Unicancer | Gustave Roussy | Vall d’Hebron Institute of Oncology (VHIO) | UCL

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer out on Nature Medicine nature.com/articles/s4159… Trial analyzed circulating tumor DNA🧬 and germline DNA in patients randomized to receive androgen receptor pathway inhibitors (ARPIs)💊, taxanes, or

ESMO announces the publication of the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S), a new framework to assess the tumour-agnostic potential of #CancerTherapies with the aim to optimise the drug development process Annals of Oncology. 🔗ow.ly/rqmR50T6gHt

Advances in precision medicine led to approval of tumour-agnostic molecularly guided therapies. The minimum requirements for claiming tumour-agnostic potential remain elusive. Different scenarios of minimum ORR, number of tumour types investigated & number of evaluable patients

I am commonly asked what the benchmarks are for a target-drug pair to have tumor-agnostic potential. See the new ETAC-S! Annals of Oncology ESMO - Eur. Oncology Vivek Subbiah, MD Juliana Beal, MD G Curigliano MD PhD Razelle Kurzrock, MD Sewanti Limaye 🇮🇳🇺🇸 Stefan Michiels Joaquin Mateo Niamh Coleman, MD PhD FabriceAndre Elena Garralda

tenemos 2 ofertas abiertas para tecnic@s de laboratorio en nuestro laboratorio de Vall d’Hebron Institute of Oncology (VHIO) - una para trabajar en NGS/biopsia liquida y otra para trabajar con modelos PDX y experimentos in vivo - se agradece difusión :-) vhio.net/2024/09/06/ref… vhio.net/2024/09/02/202…

#hiring #cancerresearch we have 2 open positions for technicians in the lab Vall d’Hebron Institute of Oncology (VHIO) #Barcelona, one to work on NGS assays and the other one to work with our PDX collection and in-vivo experiments. Starting date ASAP. vhio.net/2024/09/06/ref… From vhio.net📷

The use of PARP inhibitors in #mCRPC with BRCA1/2 alterations. Joaquin Mateo Vall d’Hebron Institute of Oncology (VHIO) and Alicia Morgans, MD, MPH Dana-Farber discuss the poor prognosis associated with these mutations but highlight the effectiveness of PARP inhibitors like olaparib and rucaparib > bit.ly/3VVDJFt

Check out our latest paper looking at real-world outcomes and biomarker associations for patients with mCRPC on single-agent PARP inhibitors!

Moments after you agree to write a review

At #MAP2024 we're joined by keynote speakers Joakim Lundeberg (KTH Royal Institute of Technology) discussing clinical translation of new spatial transcriptomics technologies & Elli Papaemmanuil, PhD (Memorial Sloan Kettering Cancer Center)discussing clonal genomics 👉 bit.ly/455dqRj ESMO - Eur. Oncology | Unicancer

First results from #ZZFIRST: a randomized phase II trial of enzalutamide with or without talazoparib in metastatic hormone-naïve #ProstateCancer. Presented by Joaquin Mateo Vall d’Hebron Institute of Oncology (VHIO). #ESMO24 written coverage by Julian Chavarriaga > bit.ly/3MMkr1i ESMO - Eur. Oncology